MXPA04005782A - Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido. - Google Patents

Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.

Info

Publication number
MXPA04005782A
MXPA04005782A MXPA04005782A MXPA04005782A MXPA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A
Authority
MX
Mexico
Prior art keywords
polypeptide
methods
level modulator
camp level
phosphodiesterase
Prior art date
Application number
MXPA04005782A
Other languages
English (en)
Spanish (es)
Inventor
Mckenna Sean
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MXPA04005782A publication Critical patent/MXPA04005782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MXPA04005782A 2001-12-14 2001-12-14 Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido. MXPA04005782A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/014730 WO2003051344A1 (en) 2001-12-14 2001-12-14 Methods of inducing ovulation_using a non-polypeptide camp level modulator

Publications (1)

Publication Number Publication Date
MXPA04005782A true MXPA04005782A (es) 2004-09-13

Family

ID=8164724

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005782A MXPA04005782A (es) 2001-12-14 2001-12-14 Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.

Country Status (18)

Country Link
US (1) US7507707B2 (enExample)
EP (2) EP1463493B1 (enExample)
JP (1) JP4532115B2 (enExample)
KR (2) KR20040075004A (enExample)
CN (1) CN1582146A (enExample)
AT (2) ATE526013T1 (enExample)
AU (1) AU2002217111B2 (enExample)
BR (2) BRPI0117198B1 (enExample)
CA (1) CA2469939C (enExample)
DE (1) DE60130813T2 (enExample)
DK (2) DK1463493T3 (enExample)
EA (1) EA011213B1 (enExample)
ES (1) ES2293965T3 (enExample)
IL (3) IL162506A0 (enExample)
MX (1) MXPA04005782A (enExample)
PT (2) PT1463493E (enExample)
UA (1) UA80418C2 (enExample)
WO (1) WO2003051344A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
CA2552540A1 (en) * 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Use of substituted pteridines for the treatment of diseases of the respiratory tract
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (en) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN103169699B (zh) * 2011-12-22 2014-11-12 中国农业大学 来曲唑在用于制备成年牛超数排卵药物中的应用
WO2014089913A1 (zh) * 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087615A (en) 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
AP1147A (en) 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
HUP0100042A3 (en) 1996-05-20 2003-01-28 Darwin Discovery Ltd Cambridge Benzofuran carboxamides medicaments containing the same and their therapeutic use
IL126557A (en) 1996-05-20 2002-09-12 Darwin Discovery Ltd Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
SK176598A3 (en) 1996-06-25 2000-06-12 Pfizer Indazole derivatives, pharmaceutical composition on their base and methods of treatment
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
DE69720757T2 (de) 1996-10-02 2004-03-04 Janssen Pharmaceutica N.V. Pde-iv hemmende 2-cyanoiminoimidazol-derivate
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
WO1998020007A1 (en) 1996-11-06 1998-05-14 Darwin Discovery Limited Quinolines and their therapeutic use
JP3237109B2 (ja) * 1996-12-13 2001-12-10 田辺製薬株式会社 医薬組成物
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU752415B2 (en) * 1998-04-23 2002-09-19 Zentaris Ivf Gmbh Method for the treatment of fertility disorders
KR20010043828A (ko) * 1998-05-26 2001-05-25 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 ｃＡＭＰ-증강 화합물 단독 또는 감수분열-자극 화합물하나 이상과의 조합에 의한 불임 치료 방법
EP1086096B1 (de) 1998-06-10 2003-07-23 ALTANA Pharma AG Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
SI1212089T1 (sl) * 1999-08-21 2006-08-31 Altana Pharma Ag Sinergisticna kombinacija roflumilasta in salmeterola
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001079526A2 (en) * 2000-04-17 2001-10-25 Bioimage A/S Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes
WO2001087287A2 (en) * 2000-05-19 2001-11-22 Applied Research Systems Ars Holding N.V. Use of pyrazole derivatives for treating infertility
ATE332708T1 (de) * 2000-06-06 2006-08-15 Glaxo Group Ltd Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US20020065324A1 (en) * 2000-08-11 2002-05-30 Stephen Palmer Methods of inducing ovulation
JP2006522151A (ja) * 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤

Also Published As

Publication number Publication date
EP1463493B1 (en) 2007-10-03
KR20040075004A (ko) 2004-08-26
AU2002217111B2 (en) 2007-05-31
EP1908463B1 (en) 2011-09-28
IL162506A (en) 2012-03-29
EP1463493A1 (en) 2004-10-06
ES2293965T3 (es) 2008-04-01
UA80418C2 (en) 2007-09-25
CA2469939C (en) 2012-06-19
EP1908463A3 (en) 2009-11-25
BRPI0117198B1 (pt) 2018-03-13
CN1582146A (zh) 2005-02-16
JP4532115B2 (ja) 2010-08-25
IL205106A0 (en) 2010-11-30
BR0117198A (pt) 2004-10-26
ATE526013T1 (de) 2011-10-15
DK1463493T3 (da) 2008-02-04
EA200400808A1 (ru) 2004-12-30
EA011213B1 (ru) 2009-02-27
AU2002217111B8 (en) 2003-06-30
AU2002217111A1 (en) 2003-06-30
WO2003051344A1 (en) 2003-06-26
PT1463493E (pt) 2008-01-04
PT1908463E (pt) 2011-12-19
IL162506A0 (en) 2005-11-20
ATE374606T1 (de) 2007-10-15
DK1908463T3 (da) 2011-11-28
JP2005516924A (ja) 2005-06-09
EP1908463A2 (en) 2008-04-09
KR20090009336A (ko) 2009-01-22
US20050148501A1 (en) 2005-07-07
CA2469939A1 (en) 2003-06-26
DE60130813D1 (de) 2007-11-15
IL205106A (en) 2013-02-28
US7507707B2 (en) 2009-03-24
KR101056916B1 (ko) 2011-08-12
DE60130813T2 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
MXPA04005782A (es) Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.
HN2002000317A (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
SE0001899D0 (sv) New compounds
PA8639701A1 (es) Composicion del anticuerpo her2
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
ATE545407T1 (de) Pharmazeutische formulierung von apomorphin für die bukkale verabreichung
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
DE50313531D1 (de) Knochennagel zum versorgen von frakturen
BR0010255A (pt) Formulação farmacêutica, kit de partes, método para tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da trombina e/ou inibição da carboxipeptidase u são requeridas ou desejadas, e, uso de uma formulação
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
BRPI0416202A (pt) formulações inibidoras de fosfodiesterase v
SE0202608D0 (sv) New sequences
PT1335730E (pt) Tratamento da ejaculacao prematura
ATE415420T1 (de) Cxcl8-antagonisten
AR049922A1 (es) Procedimientos para aumentar la cantidad de hueso
MXPA02008365A (es) Mutantes de proteinas moreogeneticas del hueso.
AR035672A1 (es) Metodo de induccion de la ovulacion en huespedes hembras; metodo de combinacion en el tratamiento estimulante del desarrollo folicular y/o de dicha induccion de la modulacion; moduladores no polipeptidicos de los niveles camp utilizables en dicho metodo de induccion de la modulacion y composiciones

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
HC Change of company name or juridical status